Abstract. To evaluate the relationship between cell proliferation and apoptosis during progression of lung carcinomas, immunohistochemistry for proliferating cell nuclear antigen (PCNA) and the in situ end labelling (TUNEL) method for identifying apoptotic bodies were performed on paraffin sections from 135 lung carcinomas. These results were correlated with the corresponding tumor volumes as a model of disease progression in lung tumors. We found that, with increasing tumor volume, the proliferation rate decreased significantly, whereas the apoptotic rate increased. There was no relationship between apoptotic and proliferative indices except in carcinomas with a tumor volume between 51 and 100 cm³. These data suggest that progression of lung carcinomas, i.e. the increase in tumor volume, is accompanied by an increase in apoptosis rather than an increase in cell proliferation.

The balance of proliferation and apoptosis plays an important role in the control of tumor growth. In general, progression of tumor growth is characterized by a net increase in the number of tumor cells. This could be due to increased proliferation and/or decreased apoptosis, or both. There is a lot of evidence in the literature that cell proliferation and apoptosis are often related to each other (1-8). However, several studies did not confirm this positive association (9-14). No study has yet systematically evaluated proliferation and apoptosis during progression of tumor growth. To evaluate the role of proliferation and apoptosis in the development of lung carcinomas, 135 lung carcinomas were quantitatively analyzed by immunohistochemistry for the proliferating cell nuclear antigen (PCNA) and by in situ end labelling for apoptotic cells and correlated with the corresponding tumor volume at the time of operation as a model of disease progression in lung cancer.

Material and Methods

Patients. One hundred and thirty-five patients with histologically proven resectable non-small cell lung cancer (NSCLC) were recruited for evaluation of tumor size and for determination of tumor cell proliferation and apoptosis. All patients had been surgically treated at the Heidelberg-Rohrbach Chest Hospital, Germany and had received no post-operative therapy. The tumor diameter and the calculation of the tumor size was done intraoperatively by the resection of the whole tumor.

Assessment of apoptosis. Apoptotic cell death was detected with the antibody for PCNA (Dianova, Hamburg, Germany; clone PC10) at a dilution of 1:10. The tumor cell proliferation was scored by selecting the maximally immunostained areas and counting PCNA-positive and -negative tumor cells at x400 magnification and with an eyepiece grid. All reactive cells were counted as positive regardless of the intensity of staining. In each case, a minimum of 500 cells were counted, and the fraction of positive cells was determined. The cases were scored without knowledge of other clinical parameters.

Correspondence to: Jürgen Mattern, M.D., Dept. E060, German Cancer Research Center, Department E060, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany. Tel: +49-6221-423221, Fax: +49-6221-423225, e-mail: j.mattern@dkfz.de

Key Words: Lung cancer, cell proliferation, apoptosis.
between proliferation and apoptosis in carcinomas with a tumor volume between 51 and 100 cm³. However, there was a positive linear correlation between PCNA index and AI for all tumors subdivided according to tumor size. As expected, there was no relationship between apoptotic and proliferative indices, except in carcinomas with a tumor volume between 51 and 100 cm³.

The fact that the growth kinetics of tumors change with increasing tumor size is common for experimental tumors (15). As a tumor grows, changes occur in cell proliferation and cell loss. It is also common that, with increasing tumor size, tumors develop regions of necrosis. Using published data on six types of transplanted mouse tumors, it can be seen that the general tendency was that the retardation of tumor growth was due more to increase in cell loss than to decrease in growth fraction (15).

Data with human tumors are scarce. Vakkala et al. (16), using primary and recurrent tumors of the breast as model for tumor progression, found that apoptosis and proliferation are increased during breast cancer progression. Mommers et al. (17) found, for poorly-differentiated breast lesions, a significant increase in mitotic index (MI) and apoptotic index (AI) from hyperplasia to poorly-differentiated DCIS (ductal carcinoma in situ). From DCIS to poorly-differentiated invasive carcinoma, the MI increased significantly and the AI decreased. In renal carcinomas, with an increase of cytological tumor grade and proliferative activity, a decrease of apoptotic rate was found (11). Dixon et al. (18) explored the relationship of the size of leiomyomas to their proliferative index. They found that the mitotic count and the PCNA and Ki-67 labelling indices decreased in tumors over 6 cm in tumor diameter. However, this did not reach statistical significance, perhaps because of the small number of cases.

The relationship between apoptotic and proliferative indices are not clear. Several studies described a positive correlation between apoptosis and proliferation (1-8). However, many examples exist where AI was not found to be associated with proliferation (9-14). In our present study, there was also no relationship between apoptotic and proliferative indices, except in carcinomas with a tumor volume between 51 and 100 cm³. Various regulatory mechanisms operating in the cell cycle checkpoint as well as in the apoptotic pathway are known (5). P53 is one of the important regulators involved in these processes. The p53 gene regulates the apoptotic process as well as the cell cycle (19). Mutated p53 may lead to uncontrolled proliferation and suppression of p53-dependent apoptosis. There are some studies which describe that p53 expression was associated with proliferation but not with apoptosis (4). This

### Table 1. Proliferation and apoptosis in human lung carcinomas subdivided according to tumor size.

<table>
<thead>
<tr>
<th>Tumor volume (cm³)</th>
<th>n</th>
<th>PCNA index (%)</th>
<th>Apoptotic index (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A &lt;50</td>
<td>49</td>
<td>22.3 (0-72)</td>
<td>9.1 (0-31)</td>
</tr>
<tr>
<td>B 51-100</td>
<td>28</td>
<td>25.2 (0-64)</td>
<td>11.3 (0-35)</td>
</tr>
<tr>
<td>C 101-200</td>
<td>13</td>
<td>19.5 (0-46)</td>
<td>10.3 (0-34)</td>
</tr>
<tr>
<td>D 201-250</td>
<td>24</td>
<td>15.5 (0-56)</td>
<td>13.1 (0-51)</td>
</tr>
<tr>
<td>E &gt;250</td>
<td>21</td>
<td>17.6 (0-40)</td>
<td>12.5 (0-33)</td>
</tr>
</tbody>
</table>

*mean values PCNA index: A vs E: p=0.004; Apoptotic index: A vs E: p=0.02 (Student’s t-test)*

The ratio of TUNEL-positive cancer cells to the total number of cancer cells, for at least 1,000 cells.
could indicate that mutant p53 may be more closely related to the modulation of cell proliferation than of apoptosis. However, besides or together with p53, many other proteins are also involved in the control of cell proliferation and cell death (5). Thus, depending on the activity of these proteins, the rate of cell death may exceed the proliferation rate and vice versa (20).

In conclusion, the net increase of the number of cells during progression of lung carcinomas is accompanied by an increase in apoptosis rather than an increase in cell proliferation, suggesting that in large lesions apoptotic-related mechanisms are most important and that this imbalance between apoptosis and proliferation may be responsible for retardation of tumor growth.

References


Received August 23, 2004
Accepted October 27, 2004